# FID-007 in Treating Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct03537690/  
OnCo record `nct03537690` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of FID-007 run by University of Southern California, active and no longer recruiting.

## Summary

FID-007 in Treating Participants With Advanced Solid Tumors is a phase 1 interventional study registered as NCT03537690 by University of Southern California, with 50 participants planned, started 2018-05-25. Conditions recorded: Advanced Malignant Solid Neoplasm and Refractory Malignant Solid Neoplasm. Interventions recorded: Laboratory Biomarker Analysis, PEOX-based Polymer Encapsulated Paclitaxel FID-007 and Pharmacokinetic Study.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03537690
- Phase: 1
- Setting: A Phase I Study of FID-007 in Patients With Advanced Solid Tumors
- Sponsor: University of Southern California
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT03537690: https://clinicaltrials.gov/study/NCT03537690

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [FID-007](https://onco.cc/drugs/fid-007/)
- companies: [Fulgent Genetics](https://onco.cc/companies/fulgent-genetics/)

---
JSON: https://onco.cc/api/v1/entities/nct03537690.json